IgA Nephropathy

First in Human Study to Assess Safety of VIS649 in Healthy Subjects

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

A Phase 2 Study of JADE101 in Participants With Immunoglobulin A Nephropathy

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)

IgA Nephropathy Biomarkers Evaluation Study (INTEREST)

A Study of Zigakibart in Adults With IgA Nephropathy

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

Study of ARO-CFB in Adult Healthy Volunteers

IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection

A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.

Study of BHV-1400 in IgA Nephropathy

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

Managed Access Programs for EXV811, Atrasentan

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

Treatment of IgA Nephropathy According to Renal Lesions

Atacicept in Subjects With IgA Nephropathy

Study of CM313 in Subject With IgA Nephropathy